MDX 1401

Drug Profile

MDX 1401

Alternative Names: Lymphoma therapies - Medarex; MDX-1401

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD30 antigen inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hodgkin's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hodgkin's-disease in USA (IV, Infusion)
  • 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
  • 19 Apr 2009 Interim adverse events, efficacy and pharmacodynamics data from a phase I trial in Hodgkin's disease presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top